more

Mirati Therapeutics, Inc. (MRTX)

(Delayed Data from NSDQ)

$76.37 USD

-10.70 (-12.29%)

Updated Oct 18, 2019 03:56 PM ET

Zacks Rank:

3-Hold 3

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1 2 3 4 5 S&P	Strong Buy Buy Hold Sell Strong Sell 500	24.50% 17.69% 9.28% 4.86% 1.63% 10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

F Value | F Growth | A Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Industry Rank:

Top 35% (90 out of 254)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Mirati Therapeutics, Inc. (MRTX) Quote Overview » News » Mirati Therapeutics, Inc. (MRTX) Zacks News

Zacks News

Are Options Traders Betting on a Big Move in Mirati Therapeutics (MRTX) Stock?

by Zacks Equity Research Published on October 01,2019

Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.

MRTX

medical

Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group

by Zacks Equity Research Published on September 09,2019

Amgen's (AMGN) novel investigational KRAS inhibitor, AMG 510, for solid tumor shows anti-tumor activity in a larger group of NSCLC patients.

ALXN AMGN BIIB MRTX

biotechs

Mirati Inks Deal with Novartis to Evaluate Tumor Candidate

by Zacks Equity Research Published on July 10,2019

Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.

AMGN MRTX ALNY AGTC

biotechs

Implied Volatility Surging for Mirati Therapeutics (MRTX) Stock Options

by Zacks Equity Research Published on June 14,2019

Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.

MRTX

biotechs

Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity

by Zacks Equity Research Published on June 04,2019

At ASCO, Amgen (AMGN) presented encouraging initial data set for AMG 510, its novel investigational KRAS inhibitor for solid tumor.

RHHBY BMY AMGN MRTX

biotechs

Why Cancer-Fighting Stocks & ETFs Are Soaring

by Neena Mishra Published on June 03,2019

The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.

LLY AZN BMY MRK CNCR CELG MRTX AMGN NKTR IOVA CHNA

medical

Options Traders Expect Huge Moves in Mirati Therapeutics (MRTX) Stock

by Zacks Equity Research Published on May 14,2019

Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.

MRTX

medical

Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4%

by Zacks Equity Research Published on January 09,2019

Mirati Therapeutics (MRTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

MRTX ACOR

biotechs

Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy

by Neena Mishra Published on October 08,2018

2018 Nobel Prize for medicine was awarded for immunotherapy research. Here is what investors need to know about stocks and ETF focused on this innovative area.

CNCR BLUE FPRX MRTX FATE CHNA

biotechs etfs medical